-
1
-
-
84876967879
-
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study
-
Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168: 1124-7.
-
(2013)
Br J Dermatol
, vol.168
, pp. 1124-1127
-
-
Gisondi, P.1
Conti, A.2
Galdo, G.3
-
2
-
-
39049173409
-
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: A retrospective cohort study
-
Gisondi P, Cotena C, Tessari G, Girolomoni G,. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-4.
-
(2008)
J Eur Acad Dermatol Venereol
, vol.22
, pp. 341-344
-
-
Gisondi, P.1
Cotena, C.2
Tessari, G.3
Girolomoni, G.4
-
3
-
-
42749094559
-
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis
-
Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-5.
-
(2008)
Pharmacol Res
, vol.57
, pp. 290-295
-
-
Saraceno, R.1
Schipani, C.2
Mazzotta, A.3
-
4
-
-
62649136592
-
Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis
-
Esposito M, Mazzotta A, Saraceno R, et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219-25.
-
(2009)
Int J Immunopathol Pharmacol
, vol.22
, pp. 219-225
-
-
Esposito, M.1
Mazzotta, A.2
Saraceno, R.3
-
6
-
-
84892565281
-
Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: A multicentre, cross-sectional study
-
doi: 10.1111/jdv.12066. [Epub ahead of print]
-
Mahé E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/jdv.12066. [Epub ahead of print].
-
(2012)
J Eur Acad Dermatol Venereol
-
-
Mahé, E.1
Reguiai, Z.2
Barthelemy, H.3
-
7
-
-
84855912765
-
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers
-
Di RenzoL, Bianchi A, Saraceno R, et al. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics 2012; 22: 134-42.
-
(2012)
Pharmacogenet Genomics
, vol.22
, pp. 134-142
-
-
Di, R.1
Bianchi, A.2
Saraceno, R.3
-
8
-
-
80052710308
-
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment
-
Di RenzoL, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 2011; 24: 446-51.
-
(2011)
Dermatol Ther
, vol.24
, pp. 446-451
-
-
Di, R.1
Saraceno, R.2
Schipani, C.3
-
9
-
-
84868378962
-
Variation pondérale chez les patients recevant un traitement systémique pour un psoriasis
-
Forien M, Mahé E, Sin C, et al. Variation pondérale chez les patients recevant un traitement systémique pour un psoriasis. Ann Dermatol Venereol 2012; 139: 649-51.
-
(2012)
Ann Dermatol Venereol
, vol.139
, pp. 649-651
-
-
Forien, M.1
Mahé, E.2
Sin, C.3
-
10
-
-
22244433242
-
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment
-
Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis 2005; 64: 1137-40.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1137-1140
-
-
Briot, K.1
Garnero, P.2
Le Henanff, A.3
-
11
-
-
44349177615
-
Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment
-
Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35: 855-61.
-
(2008)
J Rheumatol
, vol.35
, pp. 855-861
-
-
Briot, K.1
Gossec, L.2
Kolta, S.3
-
12
-
-
33845491244
-
Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis
-
Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-72.
-
(2006)
Am J Clin Nutr
, vol.84
, pp. 1463-1472
-
-
Marcora, S.M.1
Chester, K.R.2
Mittal, G.3
-
13
-
-
77955458413
-
Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
-
Alcorn N, Tierney A, Wu O, et al. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1571.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1571
-
-
Alcorn, N.1
Tierney, A.2
Wu, O.3
-
14
-
-
21244432426
-
Impact of infliximab on serum leptin level in patients with Crohn's disease
-
Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin level in patients with Crohn's disease. J Clin Endocrinol Metab 2005; 90: 3510-16.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 3510-3516
-
-
Franchimont, D.1
Roland, S.2
Gustot, T.3
-
16
-
-
84873180906
-
Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: A 16-week comparative study
-
Younis S, Rosner I, Rimar D, et al. Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine 2013; 61: 353-5.
-
(2013)
Cytokine
, vol.61
, pp. 353-355
-
-
Younis, S.1
Rosner, I.2
Rimar, D.3
-
17
-
-
77953509678
-
Adipose tissue, inflammation and atherosclerosis
-
Gustafson B,. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332-41.
-
(2010)
J Atheroscler Thromb
, vol.17
, pp. 332-341
-
-
Gustafson, B.1
-
18
-
-
84879117065
-
A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients
-
doi: 10.1111/j.1468-3083.2012.04611.x. [Epub ahead of print]
-
Park KK, Wu JJ, Koo J,. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.2012.04611.x. [Epub ahead of print].
-
(2012)
J Eur Acad Dermatol Venereol
-
-
Park, K.K.1
Wu, J.J.2
Koo, J.3
-
19
-
-
80051703774
-
Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment
-
Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-11.
-
(2011)
J Eur Acad Dermatol Venereol
, vol.25
, pp. 1007-1011
-
-
Puig, L.1
-
20
-
-
77955924889
-
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
-
Menter A, Gordon K, Leonardi C, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
-
(2010)
J Am Acad Dermatol
, vol.63
, pp. 448-456
-
-
Menter, A.1
Gordon, K.2
Leonardi, C.3
-
21
-
-
84876956361
-
Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: Subanalysis of the BELIEVE study
-
Paul C, van de Kerkhof P, Puig L, et al. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol 2012; 22: 762-9.
-
(2012)
Eur J Dermatol
, vol.22
, pp. 762-769
-
-
Paul, C.1
Van De Kerkhof, P.2
Puig, L.3
-
22
-
-
80051681379
-
Consistency of infliximab response across subgroups of patients with psoriasis: Integrated results from randomized controlled clinical trials
-
Reich K, Menter A, Plotnick M, et al. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. Psoriasis Forum 2007; 13: 21-6.
-
(2007)
Psoriasis Forum
, vol.13
, pp. 21-26
-
-
Reich, K.1
Menter, A.2
Plotnick, M.3
|